viewe-Therapeutics PLC

e-Therapeutics and C4X Discovery to collaborate on Parkinson's Disease treatment

The collaboration will see e-Therapeutics combine its Network-Driven Drug Discovery (NDD) platform with C4XD's Taxonomy3 technology

Parkinson's affects 10mln people worldwide

e-Therapeutics PLC (LON:ETX) and C4X Discovery Holdings PLC (LON:C4X) are to pool their knowledge to try to find a treatment for Parkinson’s Disease.

The collaboration will see e-Therapeutics combine its Network-Driven Drug Discovery (NDD) platform with C4XD's Taxonomy3 technology, which utilises genomes to identify new patient-specific targets, the company said in a statement.

READ: One year on, new boss is spearheading turnaround at drug discovery firm e-therapeutics

Parkinson's Disease is a degenerative disorder of the central nervous system estimated to affect 10 million people worldwide.

No cure is available currently and the aim of the collaboration is to identify new treatment strategies, molecular targets and, ultimately, novel drugs.

Taxonomy3 has already identified 180 novel disease-associated genes for Parkinson’s and e-therapeutics will use its NDD platform to help understand how the cellular mechanisms interact in the pathology of the disease.

Ray Barlow, e-therapeutics’ chief executive, said there remains a significant unmet medical need for truly effective treatments for Parkinson’s Disease.

"Our aim is to use the genomic associations that C4XD's Taxonomy3 technology platform has uncovered, to create new therapeutic approaches to treat this devastating disease."

He added the group is also working on genome-based functionality for its NDD platform in other areas including triple negative breast cancer.

The financial terms of the agreement were not disclosed.

Quick facts: e-Therapeutics PLC

Price: 14.25 GBX

Market: AIM
Market Cap: £59.72 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...


2 min read